20 Feb2020

EnClear Therapies Announces $10M Series A Financing

Written by 2020HCP.com. Posted in News

– Hillel Bachrach, Jason Camm and Zafrira Avnur join EnClear Therapies Board of Directors —

— Investors include 20/20 HealthCare Partners, Amgen Ventures, Peter Thiel, Global Health Sciences (GHS) Fund, Christian Angermayer’s Presight Capital, and Dolby Ventures —

CAMBRIDGE, Mass.–(BUSINESS WIRE)–EnClear Therapies, a life sciences company developing device-based therapies for the treatment of neurodegenerative disease, today announced a $10 million Series A financing led by 20/20 HealthCare Partners (“20/20 HCP”), and joined by Peter Thiel, Amgen Ventures, GHS Fund (Quark Venture LP and GF Securities), Christian Angermayer’s Presight Capital and Dolby Ventures. READ FULL ARTICLE 
06 Nov2019

Variantyx Launches Its Whole Genome Sequencing (WGS)-Based In-Silico Panel Program at National Society of Genetic Counselors Annual Conference

Written by 2020HCP.com. Posted in News

FRAMINGHAM, Mass.–(BUSINESS WIRE)–Variantyx today announced the launch of its in-silico panel program which is an extension of its Genomic Unity™ whole genome sequencing (WGS)-based testing service. Available to clinicians since 2017, Genomic Unity™ has been instrumental in resolving many complex patient cases. It pairs the patient’s complete DNA sequence with proprietary data analysis algorithms to detect genome-wide small sequence changes, structural variants, mitochondrial variants and tandem repeat expansions – all within a single assay.
05 Nov2019

SQZ Biotech to Present First Time Data Demonstrating Potential of Company’s Second Novel Cell Therapy Approach in Oncology – Activating Antigen Carriers (AACs)

Written by 2020HCP.com. Posted in News

Preclinical data demonstrate SQZ AACs ability to prime antigen-specific T cell responses and drive tumor reduction in vivo
SQZ to also present additional preclinical data on company’s first oncology approach with SQZPBMC-HPV
WATERTOWN, Mass., Nov. 5, 2019 — SQZ Biotechnologies (SQZ), a clinical stage cell therapy company developing innovative treatments for multiple therapeutic areas, today announced the first data highlighting the potential of the company’s activating antigen carrier (AAC) immunotherapy program for oncology indications. The findings will be detailed in a poster presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting. SQZ AACs are part of SQZ’s immune-oncology pipeline, which also includes SQZ Antigen Presenting Cells (APCs).

Latest News